Journal of Clinical Immunology

, Volume 33, Issue 2, pp 378–387 | Cite as

Simultaneous Positivity for Anti-DNA, Anti-Nucleosome and Anti-Histone Antibodies is a Marker for More Severe Lupus Nephritis

  • Mansu Sui
  • Qingyuan Lin
  • Zhaozhen Xu
  • Xiaojing Han
  • Rujuan Xie
  • Xiuzhi Jia
  • Xiaofang Guo
  • Weihua Zhang
  • Xiuru Guan
  • Huan Ren
Original Research

Abstract

Objective

The purpose of this study is to examine autoantibody profile of systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) and to establish the correlation between the antibody reactivity and disease activity of LN.

Methods

Autoantibodies and serological parameters were measured and analyzed in 589 SLE patients. The associations of the co-positivity of anti-dsDNA, -nucleosome and –histone antibodies (3-pos) with clinical, serological and outcome parameters were analyzed.

Results

At the study entry, the prevalence for anti-dsDNA (61.52 % vs. 34.11 %, P < 0.0001), anti-nucleosome (56.09 % vs. 37.21 %, P = 0.0002) and anti-histone (49.35 % vs. 33.33 %, P = 0.0013) antibodies in patients with LN were significantly higher than that in patients without LN. Patients with 3-pos had a higher proportion of proliferative renal lesions (class III + IV). The incidence of a poor renal outcome (7.14 % vs. 2.52 %, P = 0.0174) in LN patients with 3-pos was significantly higher than those without 3-pos. Moreover, the rate of remission (73.63 % vs. 82.37 %, P = 0.0245) was significantly reduced and recurrence increased (58.90 % vs. 23.44 %, P < 0.0001) in 3-pos patients as compared to that in non 3-pos within the LN group.

Conclusion

Our data indicate a strong association between the 3-pos and renal disease activities, especially proliferative glomerulonephritis. The ability of 3-pos to predict renal flares may lead to major additional benefits in the follow-up of these patients.

Keywords

Lupus nephritis antinuclear antibodies autoantibodies renal disease activity serological diagnosis 

Supplementary material

10875_2012_9825_MOESM1_ESM.doc (34 kb)
ESM Table 1(DOC 34 kb)
10875_2012_9825_MOESM2_ESM.doc (39 kb)
ESM Table 2(DOC 39 kb)

References

  1. 1.
    Riemekasten G, Hahn BH. Key autoantigens in SLE. Rheumatology (Oxford). 2005;44(8):975–82.CrossRefGoogle Scholar
  2. 2.
    Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Koffler D, Agnello V, Thoburn R, Kunkel HG. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med. 1971;134(3):169–79.PubMedGoogle Scholar
  4. 4.
    Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159–68.CrossRefGoogle Scholar
  5. 5.
    Shabana AA, El-Ghawet AE, Machaly SA, Abu Hashim EM, El-Kady BA, Shaat R. Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus. Clin Rheumatol. 2009;28(6):673–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Isenberg DA, Ravirajan CT, Rahman A, Kalsi J. The role of antibodies to DNA in systemic lupus erythematosus–a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus. 1997;6(3):290–304.PubMedCrossRefGoogle Scholar
  7. 7.
    Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34(2):501–37.PubMedCrossRefGoogle Scholar
  8. 8.
    Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P. Anti-nuscleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity. 2009;42(5):393–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Bigler C, Lopez-Trascasa M, Potlukova E, Moll S, Danner D, Schaller M, et al. Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis. 2008;51(4):624–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ahlin E, Mathsson L, Eloranta ML, Jonsdottir T, Gunnarsson I, Ronnblom L, et al. Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus. 2012;21(6):586–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Jaekell HP, Trabandt A, Grobe N, Werle E. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus. 2006;15(6):335–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Cortes-Hernandez J, Ordi-Ros J, Labrador M, Bujan S, Balada E, Segarra A, et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am J Med. 2004;116(3):165–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey’s end? Rheumatology (Oxford). 2007;46(7):1052–6.CrossRefGoogle Scholar
  14. 14.
    Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(4):1129–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2342–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Cairns AP, McMillan SA, Crockard AD, Meenagh GK, Duffy EM, Armstrong DJ, et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis. 2003;62(3):272–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 2006;55(6):900–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Amoura Z, Chabre H, Koutouzov S, Lotton C, Cabrespines A, Bach JF, et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum. 1994;37(11):1684–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev. 2008;7(8):606–11.PubMedCrossRefGoogle Scholar
  20. 20.
    Cervera R, Vinas O, Ramos-Casals M, Font J, Garcia-Carrasco M, Siso A, et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis. 2003;62(5):431–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Hung W, Chen Y, Lan J, Chen H, Chen D, Hsieh C, et al. Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. Lupus. 2011;20(13):1404–10.PubMedCrossRefGoogle Scholar
  22. 22.
    van der Vlag J, Berden JH. Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol. 2011;31(4):376–89.PubMedCrossRefGoogle Scholar
  23. 23.
    Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(3):444–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Fremeaux-Bacchi V, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006;21(11):3115–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens. 2003;12(6):619–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009;68(2):234–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T, et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum. 2011;63(8):2436–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Meyer OC, Nicaise-Roland P, Cadoudal N, Grootenboer-Mignot S, Palazzo E, Hayem G, et al. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther. 2009;11(3):R87.PubMedCrossRefGoogle Scholar
  29. 29.
    Becker-Merok A, Kalaaji M, Haugbro K, Nikolaisen C, Nilsen K, Rekvig OP, et al. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res Ther. 2006;8(6):R162.PubMedCrossRefGoogle Scholar
  30. 30.
    Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum. 2004;50(3):866–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J, et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus. 2011;20(1):28–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Grootscholten C, van Bruggen MC, van der Pijl JW, de Jong EM, Ligtenberg G, Derksen RH, et al. Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum. 2003;48(5):1355–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Mosca M, Pasquariello A, Tavoni A, Moriconi L, Moneta I, Innocenti M, et al. Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus. Lupus. 1997;6(4):371–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Austin III HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983;75(3):382–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol. 2008;4(9):464–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61(4):1502–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Strasser A, Huang DC, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta. 1997;1333(2):F151–78.PubMedGoogle Scholar
  40. 40.
    Dieker JW, Fransen JH, van Bavel CC, Briand JP, Jacobs CW, Muller S, et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum. 2007;56(6):1921–33.PubMedCrossRefGoogle Scholar
  41. 41.
    van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 2008;58(7):1892–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Jorgensen MH, Rekvig OP, Jacobsen RS, Jacobsen S, Fenton KA. Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus. Immunol Lett. 2011;138(2):179–86.PubMedCrossRefGoogle Scholar
  43. 43.
    Fismen S, Hedberg A, Fenton KA, Jacobsen S, Krarup E, Kamper AL, et al. Circulating chromatin-anti-chromatin antibody complexes bind with high affinity to dermo-epidermal structures in murine and human lupus nephritis. Lupus. 2009;18(7):597–607.PubMedCrossRefGoogle Scholar
  44. 44.
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Mansu Sui
    • 1
  • Qingyuan Lin
    • 2
    • 3
  • Zhaozhen Xu
    • 4
  • Xiaojing Han
    • 1
  • Rujuan Xie
    • 1
  • Xiuzhi Jia
    • 2
    • 3
  • Xiaofang Guo
    • 1
  • Weihua Zhang
    • 5
  • Xiuru Guan
    • 4
  • Huan Ren
    • 2
    • 3
  1. 1.Department of NephrologyFirst Hospital Affiliated to Harbin Medical UniversityHarbinChina
  2. 2.Department of ImmunologyHarbin Medical UniversityHarbinChina
  3. 3.Immunity & Infection Key laboratory of Heilongjiang ProvinceHarbinChina
  4. 4.Department of Clinical Laboratory MedicineFirst Hospital Affiliated to Harbin Medical UniversityHarbinChina
  5. 5.Department of PathophysiologyHarbin Medical UniversityHarbinChina

Personalised recommendations